Epsilon M&A Deal Report - LGC Drug Development Solutions (DDS)
Transaction Multiples for the Valuation of Private Companies
Alliance Pharma / LGC Drug Development Solutions (DDS)
No EMAT :
111924
Announced Date :
16/05/2022
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Alliance Pharma
Target :
LGC Drug Development Solutions (DDS)
Country :
United Kingdom
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
DDS is a contract research organization (CRO) that provides Bioanalytical solutions (BAS) and Analytical & Materials Science Solutions (AMS). > Offers GLP and GCP bioanalysis of small molecules,...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|||||||
| Current |
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 32
| Date | Acquirer | Target | Country | Multiples | See details |
| 24/01/2023 | Private Group led by Apax Partners | Porsolt | Mayenne | ** | 111888 |
| 22/01/2022 | EuroEyes International Eye Clinic | London Vision Clinic Partners | England | ** | 111883 |
Source: Epsilon Research / EMAT
